person · Reporting owner

Bruehlman Ronald E

Disclosed activity across 3 companies

Tapewire entity: 37285
SEC CIK: 0001604076

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GoodRx Holdings, Inc.GDRX · Entity 4838	Director	June 16, 2026	June 18, 2026
IQVIA HOLDINGS INC.IQV · Entity 3058	See Remarks	February 08, 2026	February 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GoodRx Holdings, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	207,352	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Grant · Acquired 73,434 · Balance 207,352 F1: Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units vest in full on the earlier of (i) the one-year anniversary of June 16, 2026 and (ii) the date of the 2027 Annual Meeting of Stockholders, subject to Reporting Person's continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2031; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors).

Filing footnotes · ownership attribution and instrument terms

F1: Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units vest in full on the earlier of (i) the one-year anniversary of June 16, 2026 and (ii) the date of the 2027 Annual Meeting of Stockholders, subject to Reporting Person's continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2031; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors).

IQVIA HOLDINGS INC.

Report date February 08, 2026 · Filed February 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	44,103	Ending reported balance After 2026-02-08 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-02-08 · Grant · Acquired 16,335 · Balance 50,904 F1: Acquired upon achievement of certain performance criteria pursuant to the performance-based restricted stock units granted on February 13, 2023. The performance conditions applicable to the award were determined to have been satisfied by the Company's Leadership Development and Compensation Committee on February 8, 2026. Row 2 · 2026-02-08 · Tax withholding · Disposed 6,801 · Balance 44,103
Common StockSEC Table I · non-derivative	IndirectBy Trust	11,893	Reported balance Holding disclosure · report date 2026-02-08 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 11,893 F2: Shares held in Ronald E. Bruehlman Revocable Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Acquired upon achievement of certain performance criteria pursuant to the performance-based restricted stock units granted on February 13, 2023. The performance conditions applicable to the award were determined to have been satisfied by the Company's Leadership Development and Compensation Committee on February 8, 2026.

F2: Shares held in Ronald E. Bruehlman Revocable Trust.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

IMS Health Holdings, Inc.

Report date October 03, 2016 · Filed October 03, 2016

Section 16 reporting ended · disclosed 2016-10-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2016-10-03 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2016-10-03 · Grant · Acquired 20,935 · Balance 112,655 F1: On May 3, 2016, the issuer and Quintiles Transnational Holdings, Inc. ("Quintiles") entered into an Agreement and Plan of Merger pursuant to which on October 3, 2016 the issuer merged with and into Quintiles (the "merger"), the separate existence of the issuer ceased and Quintiles will continue as the surviving corporation, operating under the name Quintiles IMS Holdings, Inc. F2: On February 10, 2015 the reporting person was granted 17,563 performance-based restricted stock units. The shares are earned based on the company's financial results over a three-year period (January 1, 2015 - December 31, 2017). In connection with the merger and based on the performance criteria achieved, 20,935 shares of issuer common stock were issued to the recipient. The performance-based restricted stock unit was assumed by Quintiles in the merger and replaced with a time-based restricted stock unit of 8,039 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger. The shares will vest on December 31, 2017 Row 2 · 2016-10-03 · Grant · Acquired 35,828 · Balance 148,483 F3: On February 2, 2016, the reporting person was granted 26,019 performance-based restricted stock units. The shares are earned based on the company's financial results over a three-year period (January 1, 2016 - December 31, 2018). In connection with the merger and based on the performance criteria achieved, 35,828 shares of issuer common stock were issued to the recipient. The performance-based restricted stock unit was assumed by Quintiles in the merger and replaced with a time-based restricted stock unit of 13,757 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger. The shares will vest on December 31, 2018. Row 3 · 2016-10-03 · Disposition to issuer · Disposed 148,483 · Balance 0 F4: Disposed of pursuant to merger agreement in exchange for 57,017 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger.
Employees Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.20 · Expires 2021-07-16	Direct	Reported balance After 2016-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-03 · Disposition to issuer · Disposed 60,000 · Balance 0 F5: This option was assumed by Quintiles in the merger and replaced with an option to purchase 23,040 shares of Quintiles IMS Holdings, Inc. common stock at a price of $29.17 per share.
Employees Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.00 · Expires 2021-07-16	Direct	Reported balance After 2016-10-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-10-03 · Disposition to issuer · Disposed 60,000 · Balance 0 F6: This option was assumed by Quintiles in the merger and replaced with an option to purchase 23,040 shares of Quintiles IMS Holdings, Inc. common stock at a price of $18.23 per share.
Employees Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2021-07-16	Direct	Reported balance After 2016-10-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-10-03 · Disposition to issuer · Disposed 230,000 · Balance 0 F7: This option was assumed by Quintiles in the merger and replaced with an option to purchase 88,320 shares of Quintiles IMS Holdings, Inc. common stock at a price of $11.46 per share.
Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $25.02 · Expires 2025-02-10	Direct	Reported balance After 2016-10-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2016-10-03 · Disposition to issuer · Disposed 11,798 · Balance 0 F8: This stock appreciation right was assumed by Quintiles in the merger and replaced with a stock appreciation right to purchase 4,530 shares of Quintiles IMS Holdings, Inc. common stock at a price of $65.16 per share.
Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $25.02 · Expires 2025-02-10	Direct	Reported balance After 2016-10-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2016-10-03 · Disposition to issuer · Disposed 35,397 · Balance 0 F10: This stock appreciation right was assumed by Quintiles in the merger and replaced with a stock appreciation right to purchase 13,592 shares of Quintiles IMS Holdings, Inc. common stock at a price of $65.16 per share. F9: This stock appreciation right vests in three annual installments beginning on February 10, 2017.
Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $23.00 · Expires 2026-02-02	Direct	Reported balance After 2016-10-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2016-10-03 · Disposition to issuer · Disposed 79,745 · Balance 0 F12: This stock appreciation right was assumed by Quintiles in the merger and replaced with a stock appreciation right to purchase 30,622 shares of Quintiles IMS Holdings, Inc. common stock at a price of $59.90 per share. F11: This stock appreciation right vests in four annual installments beginning on February 2, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: On May 3, 2016, the issuer and Quintiles Transnational Holdings, Inc. ("Quintiles") entered into an Agreement and Plan of Merger pursuant to which on October 3, 2016 the issuer merged with and into Quintiles (the "merger"), the separate existence of the issuer ceased and Quintiles will continue as the surviving corporation, operating under the name Quintiles IMS Holdings, Inc.

F2: On February 10, 2015 the reporting person was granted 17,563 performance-based restricted stock units. The shares are earned based on the company's financial results over a three-year period (January 1, 2015 - December 31, 2017). In connection with the merger and based on the performance criteria achieved, 20,935 shares of issuer common stock were issued to the recipient. The performance-based restricted stock unit was assumed by Quintiles in the merger and replaced with a time-based restricted stock unit of 8,039 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger. The shares will vest on December 31, 2017

F3: On February 2, 2016, the reporting person was granted 26,019 performance-based restricted stock units. The shares are earned based on the company's financial results over a three-year period (January 1, 2016 - December 31, 2018). In connection with the merger and based on the performance criteria achieved, 35,828 shares of issuer common stock were issued to the recipient. The performance-based restricted stock unit was assumed by Quintiles in the merger and replaced with a time-based restricted stock unit of 13,757 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger. The shares will vest on December 31, 2018.

F4: Disposed of pursuant to merger agreement in exchange for 57,017 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger.

F5: This option was assumed by Quintiles in the merger and replaced with an option to purchase 23,040 shares of Quintiles IMS Holdings, Inc. common stock at a price of $29.17 per share.

F6: This option was assumed by Quintiles in the merger and replaced with an option to purchase 23,040 shares of Quintiles IMS Holdings, Inc. common stock at a price of $18.23 per share.

F7: This option was assumed by Quintiles in the merger and replaced with an option to purchase 88,320 shares of Quintiles IMS Holdings, Inc. common stock at a price of $11.46 per share.

F8: This stock appreciation right was assumed by Quintiles in the merger and replaced with a stock appreciation right to purchase 4,530 shares of Quintiles IMS Holdings, Inc. common stock at a price of $65.16 per share.

F9: This stock appreciation right vests in three annual installments beginning on February 10, 2017.

F10: This stock appreciation right was assumed by Quintiles in the merger and replaced with a stock appreciation right to purchase 13,592 shares of Quintiles IMS Holdings, Inc. common stock at a price of $65.16 per share.

F11: This stock appreciation right vests in four annual installments beginning on February 2, 2017.

F12: This stock appreciation right was assumed by Quintiles in the merger and replaced with a stock appreciation right to purchase 30,622 shares of Quintiles IMS Holdings, Inc. common stock at a price of $59.90 per share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2026 Filed Jun 18, 2026 00:30 UTC	GoodRx Holdings, Inc. GDRX · Entity 4838	GrantClass A Common Stock	73,434	$0.00	$0.00	Disclosure SEC source: 0001809519-26-000125 · wk-form4_1781742642.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,352 F1 · shares: Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units vest in full on the earlier of (i) the one-year anniversary of June 16, 2026 and (ii) the date of the 2027 Annual Meeting of Stockholders, subject to Reporting Person's continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2031; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). Read SEC document
May 27, 2026 Filed May 29, 2026 21:58 UTC	GoodRx Holdings, Inc. GDRX · Entity 4838	GrantClass A Common Stock	4,642	$0.00	$0.00	Disclosure SEC source: 0001809519-26-000117 · wk-form4_1780091882.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,918 F1 · shares: Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units will vest as to 2% of the underlying shares on May 31, 2026, and the remining 98% will vest in substantially equal monthly installments on last day of each month over the following 7 months, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2031; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). Read SEC document
February 08, 2026 Filed Feb 10, 2026 22:45 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	6,801	$187.49	$1,275,119.49	Disclosure SEC source: 0001628280-26-006952 · wk-form4_1770763520.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,103 Read SEC document
February 08, 2026 Filed Feb 10, 2026 22:45 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantCommon Stock	16,335	$0.00	$0.00	Disclosure SEC source: 0001628280-26-006952 · wk-form4_1770763520.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,904 F1 · shares: Acquired upon achievement of certain performance criteria pursuant to the performance-based restricted stock units granted on February 13, 2023. The performance conditions applicable to the award were determined to have been satisfied by the Company's Leadership Development and Compensation Committee on February 8, 2026. Read SEC document
January 01, 2026 Filed Jan 5, 2026 22:18 UTC	GoodRx Holdings, Inc. GDRX · Entity 4838	GrantClass A Common Stock	18,251	$0.00	$0.00	Disclosure SEC source: 0001809519-26-000003 · wk-form4_1767651526.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,276 F1 · shares: Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units will vest in substantially equal monthly installments beginning on January 31, 2026 and ending on December 31, 2026, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2031; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). Read SEC document
November 08, 2025 Filed Nov 10, 2025 22:13 UTC	GoodRx Holdings, Inc. GDRX · Entity 4838	Exercise / conversionDeferred Stock Unit · Derivative	21,691	$0.00	$0.00	Disclosure SEC source: 0001809519-25-000145 · wk-form4_1762812823.xml · derivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,384 Underlying: Class A Common Stock · 21,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F1 · derivative.exercise_date: The deferred stock unit award vested as to one-third of the shares underlying the award on November 8, 2025. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). F1 · derivative.expiration_date: The deferred stock unit award vested as to one-third of the shares underlying the award on November 8, 2025. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). Read SEC document
November 08, 2025 Filed Nov 10, 2025 22:13 UTC	GoodRx Holdings, Inc. GDRX · Entity 4838	Exercise / conversionClass A Common Stock	21,691	Not disclosed	Not disclosed	Disclosure SEC source: 0001809519-25-000145 · wk-form4_1762812823.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The deferred stock unit award vested as to one-third of the shares underlying the award on November 8, 2025. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). F2 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document
June 03, 2025 Filed Jun 4, 2025 22:49 UTC	GoodRx Holdings, Inc. GDRX · Entity 4838	GrantClass A Common Stock	57,050	$0.00	$0.00	Disclosure SEC source: 0001809519-25-000090 · wk-form4_1749077349.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,334 F1 · shares: Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units vest in full on the earlier of (i) the one-year anniversary of June 3, 2025 and (ii) the date of the 2026 Annual Meeting of Stockholders, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2030; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). Read SEC document
February 10, 2025 Filed Feb 12, 2025 22:12 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	907	$206.97	$187,721.79	Disclosure SEC source: 0001478242-25-000037 · wk-form4_1739398341.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,569 Read SEC document
January 28, 2025 Filed Jan 30, 2025 22:55 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantStock Appreciation Right · Derivative	31,603	$0.00 Strike: $203.43	$0.00	Disclosure SEC source: 0001478242-25-000008 · wk-form4_1738277713.xml · derivative · entry 4 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,603 Underlying: Common Stock · 31,603 shares Expires 2035-01-28 F3 · derivative.exercise_date: This stock appreciation right vests in three annual installments beginning on January 28, 2026. Read SEC document
January 28, 2025 Filed Jan 30, 2025 22:55 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	2,201	$203.43	$447,749.43	Disclosure SEC source: 0001478242-25-000008 · wk-form4_1738277713.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,476 Read SEC document
January 28, 2025 Filed Jan 30, 2025 22:55 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantCommon Stock	6,286	$0.00	$0.00	Disclosure SEC source: 0001478242-25-000008 · wk-form4_1738277713.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,677 F1 · shares: Acquired upon achievement of certain performance criteria pursuant to the performance-based restricted stock units granted on February 10, 2022. The performance conditions applicable to the award were determined to have been satisfied by the Company's Leadership Development and Compensation Committee on January 28, 2025. Read SEC document
January 01, 2025 Filed Jan 4, 2025 00:07 UTC	GoodRx Holdings, Inc. GDRX · Entity 4838	GrantClass A Common Stock	10,653	$0.00	$0.00	Disclosure SEC source: 0001809519-25-000002 · wk-form4_1735949262.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,284 F1 · shares: Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units will vest in substantially equal monthly installments beginning on January 31, 2025 and ending on December 31, 2025, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2030; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). Read SEC document
November 08, 2024 Filed Nov 12, 2024 22:39 UTC	GoodRx Holdings, Inc. GDRX · Entity 4838	GrantDeferred Stock Unit · Derivative	65,075	$0.00	$0.00	Disclosure SEC source: 0001809519-24-000202 · wk-form4_1731451158.xml · derivative · entry 3 Bruehlman Ronald E · CIK 0001604076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,075 Underlying: Class A Common Stock · 65,075 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The deferred stock unit award vests as to one-third of the shares underlying the award on each of the first three anniversaries of the grant date, beginning on November 8, 2025, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). F4 · derivative.expiration_date: The deferred stock unit award vests as to one-third of the shares underlying the award on each of the first three anniversaries of the grant date, beginning on November 8, 2025, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). Read SEC document
November 08, 2024 Filed Nov 12, 2024 22:39 UTC	GoodRx Holdings, Inc. GDRX · Entity 4838	GrantClass A Common Stock	20,503	$0.00	$0.00	Disclosure SEC source: 0001809519-24-000202 · wk-form4_1731451158.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,631 F2 · balance_after: Reflects deferred stock units. Each restricted stock unit represents a contingent right to receive one share of Class A common stock. The restricted stock units vest in full on the earlier of (i) June 6, 2025 and (ii) the date of the 2025 Annual Meeting of Stockholders, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). Read SEC document
November 08, 2024 Filed Nov 12, 2024 22:39 UTC	GoodRx Holdings, Inc. GDRX · Entity 4838	GrantClass A Common Stock	1,128	$0.00	$0.00	Disclosure SEC source: 0001809519-24-000202 · wk-form4_1731451158.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,128 F1 · balance_after: Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units will vest in substantially equal monthly installments on the last calendar day for each remaining month of the 2024 calendar year, beginning on November 30, 2024, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). Read SEC document
February 10, 2024 Filed Feb 13, 2024 22:08 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	907	$218.20	$197,907.40	Disclosure SEC source: 0001478242-24-000027 · wk-form4_1707862086.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,391 Read SEC document
February 09, 2024 Filed Feb 13, 2024 22:08 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	1,033	$218.20	$225,400.60	Disclosure SEC source: 0001478242-24-000027 · wk-form4_1707862086.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,298 Read SEC document
February 07, 2024 Filed Feb 8, 2024 22:18 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantStock Appreciation Right · Derivative	20,719	$0.00 Strike: $214.34	$0.00	Disclosure SEC source: 0001478242-24-000016 · wk-form4_1707430726.xml · derivative · entry 4 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,719 Underlying: Common Stock · 20,719 shares Expires 2034-02-07 F3 · derivative.exercise_date: The stock appreciation right vests in three annual installments beginning on February 7, 2025. Read SEC document
February 06, 2024 Filed Feb 8, 2024 22:18 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	10,514	$215.41	$2,264,820.74	Disclosure SEC source: 0001478242-24-000016 · wk-form4_1707430726.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,331 Read SEC document
February 06, 2024 Filed Feb 8, 2024 22:18 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantCommon Stock	24,141	$0.00	$0.00	Disclosure SEC source: 0001478242-24-000016 · wk-form4_1707430726.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,845 F1 · shares: Acquired upon achievement of certain performance criteria pursuant to the performance-based restricted stock units granted on February 9, 2021. The performance conditions applicable to the award were determined to have been satisfied by the Company's Leadership Development and Compensation Committee on February 6, 2024. Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:09 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	2,588	$216.29	$559,758.52	Disclosure SEC source: 0001478242-23-000089 · wk-form4_1691442559.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,704 Read SEC document
February 13, 2023 Filed Feb 15, 2023 23:01 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantStock Appreciation Right · Derivative	20,600	$0.00 Strike: $232.11	$0.00	Disclosure SEC source: 0001478242-23-000048 · wf-form4_167650206856410.xml · derivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,600 Underlying: Common Stock · 20,600 shares Expires 2033-02-13 F1 · derivative.exercise_date: The stock appreciation right vests in three annual installments beginning on February 13, 2024. Read SEC document
February 10, 2023 Filed Feb 13, 2023 22:04 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	614	$222.84	$136,823.76	Disclosure SEC source: 0001478242-23-000028 · wf-form4_167632584887189.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,292 Read SEC document
February 09, 2023 Filed Feb 13, 2023 22:04 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	717	$230.31	$165,132.27	Disclosure SEC source: 0001478242-23-000028 · wf-form4_167632584887189.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,906 Read SEC document
August 03, 2022 Filed Aug 5, 2022 21:16 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	2,588	$233.21	$603,547.48	Disclosure SEC source: 0001478242-22-000090 · wf-form4_165973415234229.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,623 Read SEC document
February 10, 2022 Filed Feb 14, 2022 22:06 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantStock Appreciation Right · Derivative	21,849	$0.00 Strike: $250.43	$0.00	Disclosure SEC source: 0001478242-22-000022 · wf-form4_164487637172562.xml · derivative · entry 4 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,849 Underlying: Common Stock · 21,849 shares Expires 2032-02-10 F3 · derivative.exercise_date: The stock appreciation right vests in three annual installments beginning on February 10, 2023. Read SEC document
February 10, 2022 Filed Feb 14, 2022 22:06 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantCommon Stock	5,869	$0.00	$0.00	Disclosure SEC source: 0001478242-22-000022 · wf-form4_164487637172562.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,224 F1 · shares: Represents a grant of restricted stock units that will vest in three annual installments beginning on February 10, 2023. Read SEC document
February 09, 2022 Filed Feb 11, 2022 22:08 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	705	$255.57	$180,176.85	Disclosure SEC source: 0001478242-22-000020 · wf-form4_164461729807520.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,342 Read SEC document
October 25, 2021 Filed Feb 17, 2022 22:03 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	SaleCommon Stock	4	$256.93	$1,027.72	Disclosure SEC source: 0001478242-22-000043 · wf-form4_164513535199187.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,224 F1 · acquired: The purchase and sale transactions were made without Mr. Bruehlman's knowledge by an independent financial broker/advisor who manages an investment account on Mr. Bruehlman's behalf. Read SEC document
September 23, 2021 Filed Feb 17, 2022 22:03 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	PurchaseCommon Stock	4	$262.82	$1,051.28	Disclosure SEC source: 0001478242-22-000043 · wf-form4_164513535199187.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,228 F1 · acquired: The purchase and sale transactions were made without Mr. Bruehlman's knowledge by an independent financial broker/advisor who manages an investment account on Mr. Bruehlman's behalf. Read SEC document
August 03, 2021 Filed Aug 5, 2021 21:03 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	Tax withholdingCommon Stock	2,391	$0.00	$0.00	Disclosure SEC source: 0001478242-21-000052 · wf-form4_162819736861943.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,047 Read SEC document
July 20, 2021 Filed Feb 14, 2022 22:06 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	PurchaseCommon Stock	13	$245.32	$3,189.16	Disclosure SEC source: 0001478242-22-000022 · wf-form4_164487637172562.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,355 Read SEC document
February 09, 2021 Filed Feb 11, 2021 22:17 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantStock Appreciation Right · Derivative	26,701	$0.00 Strike: $183.82	$0.00	Disclosure SEC source: 0001478242-21-000007 · wf-form4_161308182421437.xml · derivative · entry 3 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,701 Underlying: Common Stock · 26,701 shares Expires 2031-02-09 F2 · derivative.exercise_date: This stock appreciation right vests in three annual installments beginning on February 9, 2022. Read SEC document
February 09, 2021 Filed Feb 11, 2021 22:17 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantCommon Stock	6,687	$0.00	$0.00	Disclosure SEC source: 0001478242-21-000007 · wf-form4_161308182421437.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,438 Read SEC document
December 10, 2020 Filed Feb 4, 2021 22:18 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GiftCommon Stock	60	$0.00	$0.00	Disclosure SEC source: 0001478242-21-000004 · wf-form5_161247709071920.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,631 Read SEC document
December 09, 2020 Filed Feb 4, 2021 22:18 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GiftCommon Stock	60	$0.00	$0.00	Disclosure SEC source: 0001478242-21-000004 · wf-form5_161247709071920.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,691 Read SEC document
August 04, 2020 Filed Aug 5, 2020 21:02 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	PurchaseCommon Stock	10,000	$159.94	$1,599,400.00	Disclosure SEC source: 0001478242-20-000058 · edgar.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,751 F2 · price: The price reported in Column 4 is a weighted average price for shares purchased in multiple transactions. The purchase prices range from $159.75 to $160.04 per share. The reporting person has provided to the issuer, and undertakes to provide to the Commission staff or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
August 03, 2020 Filed Aug 5, 2020 21:02 UTC	IQVIA HOLDINGS INC. IQV · Entity 3058	GrantCommon Stock	16,751	$0.00	$0.00	Disclosure SEC source: 0001478242-20-000058 · edgar.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,751 F1 · shares: Represents a grant of restricted stock units that will vest in three annual installments beginning on August 3, 2021. Read SEC document
October 03, 2016 Filed Oct 3, 2016 18:54 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerStock Appreciation Right · Derivative	79,745	Not disclosed Strike: $23.00	Not disclosed	Disclosure SEC source: 0001595262-16-000063 · edgar.xml · derivative · entry 9 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,745 shares Expires 2026-02-02 F12 · price: This stock appreciation right was assumed by Quintiles in the merger and replaced with a stock appreciation right to purchase 30,622 shares of Quintiles IMS Holdings, Inc. common stock at a price of $59.90 per share. F11 · derivative.exercise_date: This stock appreciation right vests in four annual installments beginning on February 2, 2017. Read SEC document
October 03, 2016 Filed Oct 3, 2016 18:54 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerStock Appreciation Right · Derivative	35,397	Not disclosed Strike: $25.02	Not disclosed	Disclosure SEC source: 0001595262-16-000063 · edgar.xml · derivative · entry 8 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,397 shares Expires 2025-02-10 F10 · price: This stock appreciation right was assumed by Quintiles in the merger and replaced with a stock appreciation right to purchase 13,592 shares of Quintiles IMS Holdings, Inc. common stock at a price of $65.16 per share. F9 · derivative.exercise_date: This stock appreciation right vests in three annual installments beginning on February 10, 2017. Read SEC document
October 03, 2016 Filed Oct 3, 2016 18:54 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerStock Appreciation Right · Derivative	11,798	Not disclosed Strike: $25.02	Not disclosed	Disclosure SEC source: 0001595262-16-000063 · edgar.xml · derivative · entry 7 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,798 shares Expires 2025-02-10 F8 · price: This stock appreciation right was assumed by Quintiles in the merger and replaced with a stock appreciation right to purchase 4,530 shares of Quintiles IMS Holdings, Inc. common stock at a price of $65.16 per share. Read SEC document
October 03, 2016 Filed Oct 3, 2016 18:54 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerEmployees Stock Option (right to buy) · Derivative	230,000	Not disclosed Strike: $4.40	Not disclosed	Disclosure SEC source: 0001595262-16-000063 · edgar.xml · derivative · entry 6 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 230,000 shares Expires 2021-07-16 F7 · price: This option was assumed by Quintiles in the merger and replaced with an option to purchase 88,320 shares of Quintiles IMS Holdings, Inc. common stock at a price of $11.46 per share. Read SEC document
October 03, 2016 Filed Oct 3, 2016 18:54 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerEmployees Stock Option (right to buy) · Derivative	60,000	Not disclosed Strike: $7.00	Not disclosed	Disclosure SEC source: 0001595262-16-000063 · edgar.xml · derivative · entry 5 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2021-07-16 F6 · price: This option was assumed by Quintiles in the merger and replaced with an option to purchase 23,040 shares of Quintiles IMS Holdings, Inc. common stock at a price of $18.23 per share. Read SEC document
October 03, 2016 Filed Oct 3, 2016 18:54 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerEmployees Stock Option (right to buy) · Derivative	60,000	Not disclosed Strike: $11.20	Not disclosed	Disclosure SEC source: 0001595262-16-000063 · edgar.xml · derivative · entry 4 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2021-07-16 F5 · price: This option was assumed by Quintiles in the merger and replaced with an option to purchase 23,040 shares of Quintiles IMS Holdings, Inc. common stock at a price of $29.17 per share. Read SEC document
October 03, 2016 Filed Oct 3, 2016 18:54 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerCommon Stock	148,483	Not disclosed	Not disclosed	Disclosure SEC source: 0001595262-16-000063 · edgar.xml · nonDerivative · entry 3 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: Disposed of pursuant to merger agreement in exchange for 57,017 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger. Read SEC document
October 03, 2016 Filed Oct 3, 2016 18:54 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	GrantCommon Stock	35,828	Not disclosed	Not disclosed	Disclosure SEC source: 0001595262-16-000063 · edgar.xml · nonDerivative · entry 2 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,483 F3 · price: On February 2, 2016, the reporting person was granted 26,019 performance-based restricted stock units. The shares are earned based on the company's financial results over a three-year period (January 1, 2016 - December 31, 2018). In connection with the merger and based on the performance criteria achieved, 35,828 shares of issuer common stock were issued to the recipient. The performance-based restricted stock unit was assumed by Quintiles in the merger and replaced with a time-based restricted stock unit of 13,757 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger. The shares will vest on December 31, 2018. Read SEC document
October 03, 2016 Filed Oct 3, 2016 18:54 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	GrantCommon Stock	20,935	Not disclosed	Not disclosed	Disclosure SEC source: 0001595262-16-000063 · edgar.xml · nonDerivative · entry 1 Bruehlman Ronald E · CIK 0001604076 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,655 F1 · price: On May 3, 2016, the issuer and Quintiles Transnational Holdings, Inc. ("Quintiles") entered into an Agreement and Plan of Merger pursuant to which on October 3, 2016 the issuer merged with and into Quintiles (the "merger"), the separate existence of the issuer ceased and Quintiles will continue as the surviving corporation, operating under the name Quintiles IMS Holdings, Inc. F2 · price: On February 10, 2015 the reporting person was granted 17,563 performance-based restricted stock units. The shares are earned based on the company's financial results over a three-year period (January 1, 2015 - December 31, 2017). In connection with the merger and based on the performance criteria achieved, 20,935 shares of issuer common stock were issued to the recipient. The performance-based restricted stock unit was assumed by Quintiles in the merger and replaced with a time-based restricted stock unit of 8,039 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger. The shares will vest on December 31, 2017 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.